Railway Pension Investments Ltd Raises Holdings in AbbVie Inc. $ABBV

Key Points

• Railway Pension Investments increased its stake in AbbVie by 33% in Q3, adding 211,800 shares to hold 853,949 shares worth $197.7 million, making AbbVie 2.7% of its portfolio and its fourth-largest holding.
• AbbVie beat Q3 estimates with $1.86 EPS (vs. $1.77 expected) and $15.78B revenue, issued Q4 2025 guidance of $3.320–3.360 EPS, and holds a consensus rating of Moderate Buy with an average price target of $245.84 after several upgrades.
• The company raised its quarterly dividend to $1.73 ($6.92 annual, ~3.0% yield) with an ex-dividend date of Jan. 16, though the reported dividend payout ratio is unusually high at about 497%.

Railway Pension Investments Ltd raised its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 33.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 853,949 shares of the company's stock after purchasing an additional 211,800 shares during the quarter. AbbVie accounts for 2.7% of Railway Pension Investments Ltd's portfolio, making the stock its 4th largest holding. Railway Pension Investments Ltd's holdings in AbbVie were worth $197,723,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Marshall & Sullivan Inc. WA acquired a new position in AbbVie during the second quarter worth $25,000. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie during the second quarter worth approximately $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie in the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $39,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on ABBV. Morgan Stanley lifted their price objective on AbbVie from $261.00 to $269.00 and gave the company an "overweight" rating in a research report on Friday, December 12th. HSBC upgraded AbbVie from a "hold" rating to a "buy" rating and raised their target price for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Erste Group Bank downgraded shares of AbbVie from a "buy" rating to a "hold" rating in a research report on Tuesday, October 14th. Piper Sandler reissued an "overweight" rating and set a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Finally, BMO Capital Markets boosted their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an "outperform" rating in a research note on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $245.84.

AbbVie Stock Performance

ABBV opened at $229.26 on Monday. The company has a fifty day moving average price of $226.69 and a two-hundred day moving average price of $214.14. The firm has a market capitalization of $405.19 billion, a PE ratio of 173.68, a P/E/G ratio of 0.96 and a beta of 0.36. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the business posted $3.00 EPS. The firm's quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is an increase from AbbVie's previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie's dividend payout ratio (DPR) is 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.